For Immediate Release 24 January 2014
Port Erin Biopharma Investments Limited
("Port Erin" or "the Company")
Holding in Company
1. Identity of the issuer or the underlying issuer |
Port Erin Biopharma Investments Limited |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
X |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
|
|
||
3. Full name of person(s) subject to the |
Colin Lee |
|||
4. Full name of shareholder(s) |
|
|||
5. Date of the transaction and date on |
23/01/2014 |
|||
6. Date on which issuer notified: |
23/01/2014 |
|||
7. Threshold(s) that is/are crossed or |
4% |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
Ordinary 0.0001p
IM00B6QH1J21 |
1,354,700 |
1,354,700 |
1,304,700 |
1,304,700 |
|
3.85% |
|
|||||||||
|
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
1,307,700 |
3.85% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
|
|
|
|
|
Proxy Voting: |
|
10. Name of the proxy holder: |
|
11. Number of voting rights proxy holder will cease |
|
12. Date on which proxy holder will cease to hold |
|
|
For further information, please visit the Company's website: www.porterinbiopharma.com or contact:
|
|
Port Erin Biopharma Investments Limited Denham Eke
|
Tel: +44 ( 0) 162 463 9396
|
Beaumont Cornish Limited Roland Cornish
|
Tel: +44 (0) 20 7628 3396 |